Volume 6.07 | Feb 27

Prostate Cell News 6.07 February 27, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
FOXP3-MicroRNA-146-NF-κB Axis and Therapy for Precancerous Lesions in Prostate
Researchers identified a FOXP3-microRNA-146 (miR-146)-NF-κB axis in vitro and in vivo in prostate cancer cells. They observed that FOXP3 dramatically induced the expression of miR-146a/b, which contributed to transcriptional inhibition of IRAK1 and TRAF6, in prostate cancer cell lines. [Cancer Res] Abstract
Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Differential Requirements for β-Catenin in Murine Prostate Cancer Originating from Basal versus Luminal Cells
Scientists explored the requirement for β-catenin in basal and luminal prostate cells during prostate cancer (CaP) progression. Genetic ablation and pharmacological inhibition of β-catenin specifically suppress basal-derived CaP progression through reduction of stemness and cell proliferation and increased γH2Ax-associated apoptosis. [J Pathol] Abstract

CXCR4 Is a Novel Target of Cancer Chemopreventative Isothiocyanates in Prostate Cancer Cells
Scientists demonstrate that chemokine receptor CXCR4 is a novel target of isothiocyanates in prostate cancer cells. Exposure of prostate cancer cells to pharmacologically applicable concentrations of phenethyl isothiocyanate, benzyl isothiocyanate, and sulforaphane resulted in downregulation of CXCR4 expression. [Cancer Prev Res] Abstract

SMAD Signaling and Redox Imbalance Cooperate to Induce Prostate Cancer Cell Dormancy
Researchers recently showed in vitro that clonogenicity of prostate cancer cells is regulated by a dormancy phenomenon that is strongly induced when cells are cultured both at low cell density and in a slightly hypertonic medium. Here, they characterized by RT-qPCR a genetic expression signature of this dormant state which combines the presence of both stemness and differentiation markers. [Cell Cycle] Abstract

Diagnostic Value of SFRP1 as a Favorable Predictive and Prognostic Biomarker in Patients with Prostate Cancer
Researchers showed that the protein and mRNA levels of secreted frizzled-related protein-1 (SFRP1) in androgen-dependent prostate cancer (PCa) cell line LNCaP were significantly higher than those in androgen-independent PCa cell lines DU145 and PC3. [PLoS One] Full Article

Repeated Sub-Optimal Photodynamic Treatments with Pheophorbide A Induce an Epithelial-Mesenchymal Transition in Prostate Cancer Cells via Nitric Oxide
Scientists examined the response of the PC3 human metastatic prostate cancer cell line following repeated low-dose pheophorbide a treatments, mimicking non-optimal photodynamic therapy treatment. [Nitric Oxide] Abstract

Paradoxical Effects of the Autophagy Inhibitor 3-Methyladenine on Docetaxel-Induced Toxicity in PC-3 and LNCaP Prostate Cancer Cells
Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells. Pre-treatment with the autophagy inhibitor, 3-methyladenine significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. [Naunyn Schmiedebergs Arch Pharmacol] Abstract

Hypoxia-Induced STAT3 Contributes to Chemoresistance and Epithelial-Mesenchymal Transition in Prostate Cancer Cells
It was found that under hypoxia, PC-3 cells were docetaxel resistant as compared to normoxic condition, and phosphor-signal transducer and activator of transcription 3 (STAT3) and N-cadherin were upregulated, while E-cadherin was downregulated. Inhibition of expression of STAT3 by S3I-201 and siRNA attenuated the levels of hypoxia-induced epithelial-mesenchymal transition. [Biochem Biophys Res Commun] Abstract

Defined Conditions for the Isolation and Expansion of Basal Prostate Progenitor Cells of Mouse and Human Origin
Researchers present a method to grow and expand both murine and human basal prostate epithelial stem/progenitor cells (PESCs) long term in serum- and feeder-free conditions. The method enriches for adherent mouse basal PESCs with a LinSCA-1+CD49f+TROP2high phenotype. [Stem Cell Rep] Full Article

CLINICAL RESEARCH

Orteronel plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (ELM-PC 4): A Double-Blind, Multicenter, Phase III, Randomized, Placebo-Controlled Trial
Scientists assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this Phase III, double-blind, placebo-controlled trial, they recruited patients with progressive metastatic castration-resistant prostate cancer and no previous chemotherapy from 324 study centers in 43 countries. [Lancet Oncol] Abstract

High-Dose Radiotherapy with Short-Term or Long-Term Androgen Deprivation in Localized Prostate Cancer (DART01/05 GICOR): A Randomized, Controlled, Phase III Trial
Researchers aimed to determine whether long-term androgen deprivation was superior to short-term androgen deprivation when combined with high-dose radiotherapy. In this open-label, multicenter, Phase III randomized controlled trial, patients were recruited from ten university hospitals throughout Spain. [Lancet Oncol] Abstract

Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
 
REVIEWS
Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
The author reviews the clinical efficacy and tolerability of oral enzalutamide in chemotherapy-naïve men with metastatic castration-resistant prostate cancer, as well as summarizes its pharmacological properties. [Drugs Aging] Abstract

Current and Emerging Immunotherapies for Castration-Resistant Prostate Cancer
The authors provide an overview of immunotherapies for castration-resistant prostate cancer (CRPC), with a focus on immune-checkpoint inhibition with ipilimumab. They consider how experience with ipilimumab in melanoma might inform future use in CRPC and describe ongoing Phase III trials. [Urology] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab
Bavarian Nordic A/S announced that updated overall survival data from an NCI sponsored combination study of its active prostate cancer immunotherapy candidate PROSTVAC and ipilimumab, an immune checkpoint inhibitor will be presented. [Press release from Bavarian Nordic A/S discussing research to be presented at the 2015 Genitourinary Cancers Symposium, Orlando] Press Release | Abstract

Cellanyx Diagnostics Announces First Clinical Data with a Novel Live Tumor Cell, Phenotypic Biomarker Test in Prostate Cancer
Cellanyx Diagnostics announced that it will present their first clinical data in prostate cancer with a novel live tumor cell phenotypic diagnostic test. Data will be presented at a poster session which demonstrate the test’s potential to stratify the risk of tumor advancement and metastasis in patients diagnosed with low and intermediate Gleason scores in prostate cancer. [Press release from Cellanyx Diagnostics discussing research to be presented at the 2015 Genitourinary Cancers Symposium, Orlando] Press Release

Innocrin Pharmaceuticals Inc. to Present Interim Results from Its Phase I/II Prostate Cancer Clinical Study and Preclinical Results that Demonstrate VT-464 Efficacy in a Clinically-Relevant Enzalutamide-Resistant Mouse Model
Innocrin Pharmaceuticals, Inc. announced that results from clinical and preclinical studies with its Phase II clinical lead, VT-464, will be presented. [Press release from Innocrin Pharmaceuticals, Inc. discussing research presented at the 2015 Genitourinary Cancers Symposium, Orlando] Press Release | Abstract

Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers
Epic Sciences announced that results from studies in metastatic castration resistant prostate cancer, neuroendocrine prostate cancer and muscle-invasive, metastatic bladder cancers using Epic’s circulating tumor cell (CTC) technology will be presented. [Press release from Epic Sciences discussing research presented at the 2015 Genitourinary Cancers Symposium, Orlando] Press Release

PROVENGE® (Sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer
Valeant Pharmaceuticals International, Inc. announced the presentation of new long-term, preliminary results from the Phase II STAND trial demonstrating a robust immune response with PROVENGE® that continues two years after completing treatment in men with biochemically-recurrent prostate cancer. [Press release from Valeant Pharmaceuticals International, Inc. discussing research presented at the 2015 Genitourinary Cancers Symposium, Orlando] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
INDUSTRY NEWS
CPRIT Awards 58 Research Grants to Advance the Fight Against Cancer
The Cancer Prevention and Research Institute of Texas (CPRIT) awarded four grants through its product development research program and 54 grants through its academic research program. With a total requested amount of $48.5 million, these grants will fund projects focused on taking promising cancer treatments and therapies from the laboratory into clinical practice. [Cancer Prevention and Research Institute of Texas]
Press Release

$3 Million Awarded as Prostate Cancer Foundation Announces First Research Awards of 2015
The Prostate Cancer Foundation (PCF) announced three new challenge awards to support discoveries for the treatment of lethal prostate cancer. PCF Challenge Awards are multi-year awards supporting cross-disciplinary teams of research scientists. [Prostate Cancer Foundation] Press Release
 
POLICY NEWS
Therapeutic Cancer Vaccine Survives Biotech Bust
The first therapeutic cancer vaccine to be approved in the United States will stay on the market despite the financial collapse of the trailblazing biotechnology company that developed it. The vaccine, Provenge, was purchased on 23 February by Valeant Pharmaceuticals of Laval, Canada, which paid US$415 million for the prostate-cancer treatment and other assets of the bankrupt Dendreon Corporation. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposium – Viruses and Human Cancer
March 29-April 3, 2015
Big Sky, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Associate – Prostate Cancer (University of Sydney)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

PhD Studentship – Prostate Cancer (University of Hull)

Postdoctoral Fellow – Cancer Biology (Brigham & Women’s Hospital – Harvard Medical School)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Research – Scientist Metabolic Adaptation in Treatment Resistant Prostate Cancer (Cancer Research UK Beatson Institute in Glasgow)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us